TITLE

Effect of requiring advance approval of chemotherapy on number and cost of ungiven doses

AUTHOR(S)
Berhoune, Malik; Aboudagga, Haîl; Jacob, Aude; Grandhay, Jean-Pierre; Dayot, Corinne; Prognon, Patrice; Bonan, Brigitte
PUB. DATE
April 2011
SOURCE
American Journal of Health-System Pharmacy;4/1/2011, Vol. 68 Issue 7, p557
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the results of a data analysis at the Georges Pompidou European Hospital in France, which compared the number and cost of ungiven doses in same-day order and advance approval procedures. The analysis revealed a higher percentage of ungiven doses in the oncology unit which used the same-day approval procedure. The article highlights that using an advance approval system could reduce patients' waiting time and allow personnel to efficiently manage their workload.
ACCESSION #
59967749

 

Related Articles

  • Lean methodology in i.v. medication processes in a children's hospital. L'Hommedieu, Timothy; Kappeler, Karl // American Journal of Health-System Pharmacy;12/15/2010, Vol. 67 Issue 24, p2115 

    Purpose. The impact of lean methodology in i.v. medication processes in a children's hospital was studied. Methods. Medication orders at a children's hospital were analyzed for 30 days to identify the specific times when most medications were changed or discontinued. Value-stream mapping was...

  • A three-year study of a first-generation chemotherapy-compounding robot. NURGAT, ZUBEIR; FARIS, DIMA; MOMINAH, MAHER; VIBAR, ARRIS; AL-JAZAIRI, ABDULRAZAQ; EWING, SHEENA; ASHOUR, MOHAMMED; QAISI, SHROUQ KAMEL; BALHARETH, SAKRA; AL-JEDAI, AHMED // American Journal of Health-System Pharmacy;6/15/2015, Vol. 72 Issue 12, p1036 

    Purpose. Results of a performance evaluation of an automated system for compounding antineoplastic preparations are reported. Methods. Three years after the pharmacy department of a hospital in Saudi Arabia installed an i.v.-compounding robot (CytoCare, Health Robotics), data captured by the...

  • Inhouse authorization center to improve reimbursement for outpatient chemotherapy infusions. Desai, Shetal S. // American Journal of Health-System Pharmacy;5/1/2011, Vol. 68 Issue 9, p828 

    Purpose. The use of an inhouse authorization center to improve reimbursement for outpatient chemotherapy infusions is described. Summary. Investigation of current processes revealed deficiencies in the coordination of an insurance authorization process at Norris Cancer Hospital, as chemotherapy...

  • Intravenous chemotherapy preparation errors: Patient safety risks identified in a pan-Canadian exploratory study. White, Rachel; Cassano-Piché, Andrea; Fields, Anthony; Cheng, Roger; Easty, Anthony // Journal of Oncology Pharmacy Practice;Feb2014, Vol. 20 Issue 1, p40 

    Background: This exploratory study was launched following a critical chemotherapy medication incident to thoroughly and proactively examine the current processes for ordering, preparing, labeling, verifying, administering, and documenting ambulatory intravenous chemotherapy in Canada, and to...

  • gemcitabine.  // Royal Society of Medicine: Medicines;2002, p265 

    This article provides information on gemcitabine, a cytotoxic/anticancer drug which is used in the clinical management of locally advanced or metastatic non-small cell lung cancer. It is also used for advanced metastatic adenocarcinoma of the pancreas. The drug is administered through injection.

  • Zavedos.  // Royal Society of Medicine: Medicines;2002, p575 

    This article presents information on the drug Zavedos. This drug is proprietary, prescription-only preparation of the anticancer drug idarubicin hydrochloride. It can be used to treat various cancers, and is available as capsules and in a form for injection.

  • Minimizing waste during preparation of blinatumomab infusions. Marini, Bernard L.; Wechter, Andrew R.; Burke, Patrick W.; Bixby, Dale; Perissinotti, Anthony J. // American Journal of Health-System Pharmacy;1/15/2016, Vol. 73 Issue 2, p19 

    The article discusses the approval of blinatumomab, the most expensive oncology drugs and a first-in-class, novel CD19-directed bispecific T-cell engager approved for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic...

  • A Simulation Study to Improve Performance in the Preparation and Delivery of Antineoplastic Medications at a Community Hospital. Lu, Tao; Wang, Shuli; Li, Jingshan; Lucas, Paul; Anderson, Mike; Ross, Kay // Journal of Medical Systems;Oct2012, Vol. 36 Issue 5, p3083 

    In this paper, we introduce a simulation study to improve the antineoplastic medication preparation and delivery performance at a pharmacy department in a large community hospital. The goal of this work is to help pharmacy reduce patients' average waiting time when receiving chemotherapy. This...

  • Novel Molecular Targets in Cancer Chemotherapy Waiting for Discovery. Kunick, Conrad // Current Medicinal Chemistry - Anti-Cancer Agents;Sep2004, Vol. 4 Issue 5, p421 

    Despite a number of advances in the past decades the medicinal cancer therapy is hampered by problems of severe unwanted side effects and the development of resistances. Many established anti-cancer drugs are directed toward targets that are not specific for cancer but are essential biochemical...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics